Archive for the ‘News’ Category

Is Increasing Drug Solubility The Answer To Improving Topical Eye Drug Delivery?

Wednesday, January 23rd, 2013

Improving the Delivery of Topical Ocular Drops

Using semifluorinated alkanes to transform poorly soluble drugs into effective therapeutics.


Novaliq GmbH, based in Heidelberg, Germany, is a drug delivery company that is developing a superior generation of ocular formulations for poorly soluble drugs. The patented ocular formulations are based on semifluorinated alkanes (SFAs), which can be easily applied in the form of eye drops or an eye spray.

Since its establishment in 2007, Novaliq has obtained four rounds of funding totalling €13.2 million from its major shareholder, Dievini Hopp Biotech Holding (a venture capital company focusing on biopharmaceutical companies in Europe). This funding is anticipated to support the company until 2015.


Click here to read the complete item. (PDF, 136 KB)

Scotia Vision Founder Michael O’Rourke presents at the 2011 annual “Controlled Release Society” meeting on “Market Development Strategies For Ocular Drug Delivery Systems”

Thursday, September 29th, 2011

“Ocular drug delivery is one of the most challenging endeavors due to the unique anatomy and physiology of the eye. This focus group will provide a forum for scientists from both industry and academia to share experiences, communicate lessons learned, and exchange information regarding novel biomaterials, formulations, delivery technologies, ocular pharmacokinetics and pharmacodynamics, and regulatory issues related to the development of ocular drug delivery systems. The mission of the focus group is to facilitate the understanding of key factors that influence and key issues that hinder effective drug delivery to the target tissues of the eye. The Ocular Drug Delivery Focus Group was established in April 2011.”

For more details visit:

For details contact Michael O’Rourke